“…Neither is it explicidly limited to the utilization of transgenic (mouse) models to mimic human diseases with all the well-known associated challenges nor to use animals as disease models for practical reasons, e.g. ( Thomas et al, 2001 ), but the use of natural genetic and functional heterogeneity of RBCs from various species such as the elliptic camel RBCs as models for elliptocytosis ( Smith et al, 1979 ; Amin and Sirs, 1985 ; Windberger et al, 2018 ; Baier et al, 2021 ), naturally sickling RBCs of deer, sheep, goat, genets and mongoose, Gulf toadfish, iguana, snakes, or fishes for sickle cell disease ( Steinberg, 2019 ), cow and sheep RBC as models for lipid alterations ( Engen and Clark, 1990 ; Nouri-Sorkhabi et al, 1996 ; Ivanov, 2007 ), and cattle ( Inaba et al, 1996 ; Jay, 1996 ) or even lamprey ( Cameron et al, 2000 ) RBCs as a model of Band 3 protein deficiency. We are looking forward to it.…”